Skip to main content

Table 1 Demographic characteristics of the study population

From: CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

  N=185  
Characteristics Males, n=60 Females n=125 P value
Age (years) 40.16667 (9.141) 38.336 (8.065) 0.1683
Weight (kg) 61.51667 ( 10.058) 57.92 (11.291) 0.0372
Height (m) 1.718644 (0.089) 1.607258 (0 .084) <0.001
Duration on EFV (months) 6.941667 (9.967) 10.30456 (12.272) 0.0661
CNS Toxicity,    
Yes 26 [32.91] 53 [67.09]  
No 34 [32.08] 72 [67.92] 0.904
Log EFV concentration 1.382 (1.274) 1.632 ( 1.069) 0.1638
Genetic polymorphisms    
CYP2B6*6 ,    
GG 17 [29.82] 40 [70.18]  
GT 29 [34.52] 55 [65.48]  
TT 13 [33.33] 26 [66.67] 0.841
CYP2B6*18,    
TT 43 [32.58] 89 [67.42]  
TC 14 [29.79] 33 [70.21]  
CC 3 [50.00] 3 [50.00] 0.608
CYP2A6*9,    
GG 33 [30.00] 77 [70.00]  
TT 8 [33.33] 16 [66.67] 0.748
CYP2A6*17,    
GG 38 [31.67] 82 [68.33]  
GA 3 [20.00] 12 [80.00]  
AA 1 [100] 0 [0] 0.212
ABCB1236 C/T    
CC 37 [32.17] 78 [67.83]  
CT 5 [31.25] 11 [68.75]  
TT 0 [0] 6 [100] 0.316
  1. The distribution of study variable outcomes grouped by sex and presented as mean and standard deviation (SD) for continuous variables and total number and [%] for categorical variables.